MedTrace Logo

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

NCT03370861 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2024-09-05

No results posted yet for this study

Summary

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

Conditions

Interventions

BIOLOGICAL

Immunotherapy

Medications that increase the activity of the immune system.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • William H McCoy IV, MD, PhD · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03370861 on ClinicalTrials.gov